Cost‐effectiveness · people aged 60 years and older living in the community
1 finding from 1 review
no estimate extracted
163683 participants
Very low
Fall‐related injuries · community‐dwelling older adults ≥ 65 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of people sustaining one or more fall‐related fractures · community‐dwelling older adults ≥ 65 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of people who experience a fall that required hospital admission · community‐dwelling older adults ≥ 65 years of age
1 finding from 1 review
no estimate extracted
4542 participants
Very low
Participants with at least some Side Effects · community‐dwelling older adults ≥ 65 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic analysis · community‐dwelling older adults ≥ 65 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Falls · people aged 60 years and older living in the community
1 finding from 1 review
no estimate extracted
1422 participants
Very low
Number of fallers · people aged 60 years and older living in the community
1 finding from 1 review
no estimate extracted
1422 participants
Very low
Outcomes (weighted · stable COPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Moderate‐to‐severe exacerbations (rate) · stable COPD
Triple therapy may leads to lower moderate‐to‐severe exacerbations (rate) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Severe exacerbations (rate) · stable COPD
Triple therapy may leads to lower severe exacerbations (rate) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Respiratory HRQoL measured by SGRQ, ≥ 4‐point decrease from baseline (lower scores indicate better HRQoL) · stable COPD
Triple therapy leads to higher respiratory HRQoL measured by SGRQ, ≥ 4‐point decrease from baseline… compared with LABA/LAMA combination (high certainty).
1 finding from 1 review
Pneumonia (labelled as an SAE) · stable COPD
Triple therapy probably leads to higher pneumonia (labelled as an SAE) compared with LABA/LAMA combination (moderate certainty).
1 finding from 1 review
SAEs · stable COPD
Triple therapy showed no clear difference in all‐cause SAEs compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Symptoms of dyspnoea · stable COPD
Triple therapy probably leads to higher symptom score TDI, ≥ 1‐unit increase (lower scores indicate worse… compared with LABA/LAMA combination (moderate certainty).
1 finding from 1 review
Change in baseline trough FEV1 · stable COPD
Triple therapy may leads to higher lung function, change in trough FEV1 (mL) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Mortality (all‐cause) · stable COPD
Triple therapy may leads to lower mortality (all‐cause) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · stable COPD
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in exacerbations (number of people experiencing ≥ 1 exacerbations) compared with LABA plus inhaled corticosteroid (ICS) (moderate certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · stable COPD
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in serious adverse events (number of people experiencing ≥ 1 SAEs) compared with LABA plus inhaled corticosteroid (ICS) (high certainty).
1 finding from 1 review
Change in SGRQ total score · stable COPD
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in quality of life as measured by SGRQ total score change from baseline… compared with LABA plus inhaled corticosteroid (ICS) (moderate certainty).
1 finding from 1 review